Organon &

Organon & Liabilities

The The Liabilities of Organon & (OGN) as of Nov 11, 2026 is 12.12 B USD. In the previous year, The Liabilities was 12.63 B USD — a change of -4.07% (lower).

Liabilities

12.12 BUSD

YoY

-4.07%

Last updated:

In 2025, Organon &'s total liabilities amounted to 12.12 B USD, a -4.07% difference from the 12.63 B USD total liabilities in the previous year.

The Organon & Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
4.15 B USD
Jan 1, 2019
3.51 B USD
Jan 1, 2020
4.62 B USD
Jan 1, 2021
12.19 B USD
Jan 1, 2022
11.85 B USD
Jan 1, 2023
12.13 B USD
Jan 1, 2024
12.63 B USD
Jan 1, 2025
12.12 B USD
The Organon & Liabilities history
YEARLiabilitiesYoY
12.12 BUSD-4.07%
12.63 BUSD+4.13%
12.13 BUSD+2.37%
11.85 BUSD-2.81%
12.19 BUSD+163.66%
4.62 BUSD+31.60%
3.51 BUSD-15.27%
4.15 BUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Organon & Stock analysis

What does Organon & do? Organon & Co. generates revenue through prescription therapies and medical devices focused on women’s health, biosimilars, and established brands. Key products include contraception and fertility solutions like Nexplanon, Implanon NXT, NuvaRing, Follistim AQ, and Elonva, alongside biosimilars for immunology and oncology. Established brands cover cardiovascular, respiratory, dermatology, and non-opioid pain management segments. The company sells directly to drug wholesalers, retailers, hospitals, government agencies, and managed healthcare providers such as health maintenance organizations and pharmacy benefit managers. Organon’s portfolio targets healthcare institutions and providers, with products distributed through established pharmaceutical channels. The company’s biosimilars and women’s health brands drive sales in specialized medical markets, while established brands serve broader therapeutic areas. Revenue streams are derived from direct sales to healthcare systems and institutions that manage patient care across multiple therapeutic categories. The firm’s strategy centers on delivering innovative health solutions via a diversified product portfolio. Prescription therapies for women’s health, including contraceptive and fertility treatments, form a significant segment of sales. Biosimilars in immunology and oncology, alongside established brands in cardiovascular and respiratory care, contribute to recurring revenue from institutional buyers. Organon & is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Organon &'s Liabilities

Organon &'s liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Organon &'s financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Organon &'s liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Organon &'s total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Organon &’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Organon & stock

The Liabilities of Organon & is 12.12 B USD in 2025.

The Liabilities of Organon & changed from 12.63 B USD to 12.12 B USD, representing a -4.07% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Organon & since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Organon & historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Organon &

All Key Metrics — Organon &